Literature DB >> 21530584

Cannabis use in young people: the risk for schizophrenia.

Paola Casadio1, Cathy Fernandes, Robin M Murray, Marta Di Forti.   

Abstract

Cannabis is one of the most commonly used illicit drugs, and despite the widely held belief that it is a safe drug, its long-term use has potentially harmful consequences. To date, the research on the impact of its use has largely been epidemiological in nature and has consistently found that cannabis use is associated with schizophrenia outcomes later in life, even after controlling for several confounding factors. While the majority of users can continue their use without adverse effects, it is clear from studies of psychosis that some individuals are more vulnerable to its effects than others. In addiction, evidence from both epidemiological and animal studies indicates that cannabis use during adolescence carries particular risk. Further studies are warranted given the increase in the concentration of the main active ingredient (Δ(9)-tetrahydrocannabinol) in street preparations of cannabis and a decreasing age of first-time exposure to cannabis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21530584     DOI: 10.1016/j.neubiorev.2011.04.007

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  57 in total

1.  Developmental pathways of adolescent cannabis use: Risk factors, outcomes and sex-specific differences.

Authors:  Samuel W Hawes; Elisa M Trucco; Jacqueline C Duperrouzel; Stefany Coxe; Raul Gonzalez
Journal:  Subst Use Misuse       Date:  2018-11-05       Impact factor: 2.164

Review 2.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 3.  Synaptic functions of endocannabinoid signaling in health and disease.

Authors:  Alfonso Araque; Pablo E Castillo; Olivier J Manzoni; Raffaella Tonini
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

4.  To legalize or not to legalize cannabis, that is the question!

Authors:  Marta Di Forti
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

Review 5.  Intervention in the context of development: pathways toward new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Zachary Warren
Journal:  Neuropsychopharmacology       Date:  2014-09-03       Impact factor: 7.853

6.  Predictors of a clinical high risk status among individuals with a family history of psychosis.

Authors:  Jacqueline Stowkowy; Jean Addington
Journal:  Schizophr Res       Date:  2013-04-20       Impact factor: 4.939

7.  Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms.

Authors:  Jordan Bechtold; Alison Hipwell; David A Lewis; Rolf Loeber; Dustin Pardini
Journal:  Am J Psychiatry       Date:  2016-05-03       Impact factor: 18.112

8.  An Examination of Marijuana Use Among a Vulnerable Population in Canada.

Authors:  Nicholas Spence; Samantha Wells; Julie George; Kathryn Graham
Journal:  J Racial Ethn Health Disparities       Date:  2014-07-12

9.  A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis.

Authors:  Jacob Cookey; Jacob McGavin; Candice E Crocker; Kara Matheson; Sherry H Stewart; Philip G Tibbo
Journal:  Can J Psychiatry       Date:  2020-02-04       Impact factor: 4.356

Review 10.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.